These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 8114606)
1. Cromakalim and cicletanine against pacing-induced myocardial ischemia in conscious rabbits. Szilvassy Z; Koltai M; Ferdinandy P; Jakab I; Lonovics J; Tarrade T; Allard M; Braquet PG Life Sci; 1994; 54(9):PL125-30. PubMed ID: 8114606 [TBL] [Abstract][Full Text] [Related]
2. Cicletanine attenuates overdrive pacing-induced global myocardial ischemia in rabbits: possible role of cardiac cyclic nucleotides. Szilvassy Z; Jakab I; Bor P; Koltai M; Tarrade T; Esanu A; Braquet PG; Lonovics J Coron Artery Dis; 1993 May; 4(5):443-52. PubMed ID: 8261221 [TBL] [Abstract][Full Text] [Related]
3. KATP channel modulation in working rat hearts with coronary occlusion: effects of cromakalim, cicletanine, and glibenclamide. Ferdinandy P; Szilvássy Z; Droy-Lefaix MT; Tarrade T; Koltai M Cardiovasc Res; 1995 Nov; 30(5):781-7. PubMed ID: 8595627 [TBL] [Abstract][Full Text] [Related]
4. Ventricular overdrive pacing-induced preconditioning and no-flow ischemia-induced preconditioning in isolated working rat hearts. Ferdinandy P; Szilvássy Z; Koltai M; Dux L J Cardiovasc Pharmacol; 1995 Jan; 25(1):97-104. PubMed ID: 7723361 [TBL] [Abstract][Full Text] [Related]
5. Zaprinast, cicletanine, and verapamil attenuate overdrive pacing-induced myocardial ischemia in conscious rabbits. Szilvassy Z; Jakab I; Ferdinandy P; Koltai M; Lonovics J; Tarrade T; Braquet PG Life Sci; 1993; 53(1):PL13-8. PubMed ID: 8390593 [TBL] [Abstract][Full Text] [Related]
6. Activation of ATP-sensitive K+ channels by cromakalim. Effects on cellular K+ loss and cardiac function in ischemic and reperfused mammalian ventricle. Venkatesh N; Stuart JS; Lamp ST; Alexander LD; Weiss JN Circ Res; 1992 Dec; 71(6):1324-33. PubMed ID: 1423930 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the relaxing effects of cicletanine and cromakalim on vascular smooth muscle. Deitmer P; Golenhofen K; Noack T J Cardiovasc Pharmacol; 1992 Jul; 20(1):35-42. PubMed ID: 1383629 [TBL] [Abstract][Full Text] [Related]
8. Analysis of pulmonary and systemic vascular responses to cromakalim, an activator of K+ATP channels. Minkes RK; Kvamme P; Higuera TR; Nossaman BD; Kadowitz PJ Am J Physiol; 1991 Mar; 260(3 Pt 2):H957-66. PubMed ID: 1825747 [TBL] [Abstract][Full Text] [Related]
9. A comparison between the effects of BMS-180448, a novel K+ channel opener, and cromakalim in rat and dog. D'Alonzo AJ; Darbenzio RB; Sewter JC; Hess TA; Grover GJ; Sleph PG; Normandin DE; Lodge NJ Eur J Pharmacol; 1995 Dec; 294(1):271-80. PubMed ID: 8788441 [TBL] [Abstract][Full Text] [Related]
11. Cardioprotection with the KATP opener cromakalim is not correlated with ischemic myocardial action potential duration. Grover GJ; D'Alonzo AJ; Parham CS; Darbenzio RB J Cardiovasc Pharmacol; 1995 Jul; 26(1):145-52. PubMed ID: 7564356 [TBL] [Abstract][Full Text] [Related]
12. Ventricular overdrive pacing-induced anti-ischemic effect: a conscious rabbit model of preconditioning. Szilvassy Z; Ferdinandy P; Bor P; Jakab I; Lonovics J; Koltai M Am J Physiol; 1994 May; 266(5 Pt 2):H2033-41. PubMed ID: 8203601 [TBL] [Abstract][Full Text] [Related]
13. Effect of cicletanine on overpacing-induced ST-segment elevation in conscious rabbits. A comparison with verapamil. Szilvássy Z; Koltai M; Szekeres L; Tarrade T; Braquet P Eur J Pharmacol; 1991 Jul; 199(3):383-6. PubMed ID: 1915586 [TBL] [Abstract][Full Text] [Related]
14. Effects of ATP-dependent K+ channel modulators on an ischemia-reperfusion rabbit isolated heart model with programmed electrical stimulation. Bellemin-Baurreau J; Poizot A; Hicks PE; Rochette L; Armstrong JM Eur J Pharmacol; 1994 Apr; 256(2):115-24. PubMed ID: 8050462 [TBL] [Abstract][Full Text] [Related]
15. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts? Tosaki A; Szerdahelyi P; Engelman RM; Das DK J Pharmacol Exp Ther; 1993 Dec; 267(3):1355-62. PubMed ID: 8263798 [TBL] [Abstract][Full Text] [Related]
16. Beneficial cardiac effects of cicletanine in conscious rabbits with metabolic syndrome. Drimba L; Hegedüs C; Yin D; Sári R; Németh J; Szilvássy Z; Peitl B J Cardiovasc Pharmacol; 2012 Aug; 60(2):208-18. PubMed ID: 22622233 [TBL] [Abstract][Full Text] [Related]
17. In vivo cardiac electrophysiologic effects of RWJ 29009, a new potassium-channel activator, in comparison to cromakalim and nicardipine. Damiano BP; Stump GL; Cheung WM; Salata JJ J Cardiovasc Pharmacol; 1993 Jul; 22(1):143-52. PubMed ID: 7690086 [TBL] [Abstract][Full Text] [Related]
18. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent. Katz LB; Giardino EC; Salata JJ; Moore JB; Falotico R J Pharmacol Exp Ther; 1993 Nov; 267(2):648-56. PubMed ID: 8246137 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular effects of KRN2391 in anesthetized dogs: a comparison with cromakalim and nitroglycerin. Kaneta S; Yokoyama T; Izumi H; Izawa T; Ogawa N Arch Int Pharmacodyn Ther; 1994; 327(2):184-93. PubMed ID: 7979827 [TBL] [Abstract][Full Text] [Related]
20. Combined administration of an IK(ATP) activator and Ito blocker increases coronary flow independently of effects on heart rate, QT interval, and ischaemia-induced ventricular fibrillation in rats. Rees SA; Tsuchihashi K; Hearse DJ; Curtis MJ J Cardiovasc Pharmacol; 1993 Sep; 22(3):343-9. PubMed ID: 7504122 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]